The research progress of patient-derived tumor xenografts
LIU Qing
ZHENG Lin
ZHANG Hao
Abstract：Patient-derived tumor xenografts (PDTX)which graft human tumor material into immunocompetent or immunodeficient mouse overcome the disadvantages of cell line-derived xeno-grafts.Patient-derived tumor xenografts maintain the cell differentiation and morphology,the archi-tecture,and molecular signatures of the original patient tumors.Vasculature,stroma,central necro-sis,and peripheral growth occur in tumor bearing mice in a way that is similar to that of the patient′s tumor,then there will be a higher correlation between drug response of tumor xenografts with the corresponding original tumors.But beyond that,patient-derived tumor xenograft models that are clin-ically representative of each major human cancer type would largely increase the success in identi-fying new active agents for targeting particular tumours.Therefore,these individualised models of human cancers would have an important significance for preclinical tumor assessment,treatment and prognosis and greatly facilitate selecting the best therapy for each individual patient.
Keywords：Patient-derived tumor xenografts(PDTX)Primary tumorIndividual treatment
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 65-68 )